System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42931411 DOI: 10.3390/vaccines14100882

Burden of Respiratory Syncytial Virus (RSV) on Severe Acute Respiratory Infection and Projected Cost Offsets of Implementing a Regional Adult RSV Vaccination Programme.

Vaccines (Basel) 14(10)

Authors: Liam Townsend, T J Bourke, Azonim Egwu, Samuel Zen Kai Yap, Fergal Howley, Brian D Kent, Conor Woods, Aileen Conway, Brendan Crowley, Colm Kerr, Rose-Anne Kenny, Colm Bergin

Affiliations

  • Department of Infectious Diseases, St James's Hospital, D08 NHY1 Dublin, Ireland.
  • Department of Clinical Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland.
  • Department of Respiratory Medicine, St James's Hospital, D08 NHY1 Dublin, Ireland.
  • Department of Clinical Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland. Department of Endocrinology, St James's Hospital, D08 NHY1 Dublin, Ireland.
  • Department of Clinical Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland. Department of Virology, St James's Hospital, D08 NHY1 Dublin, Ireland.
  • Department of Infectious Diseases, St James's Hospital, D08 NHY1 Dublin, Ireland. Department of Clinical Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland.
  • Department of Clinical Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland. Department of Medical Gerontology, St James's Hospital, D08 NHY1 Dublin, Ireland.

Abstract

Objective: RSV is a significant contributor to severe acute respiratory infection (SARI) admissions. Despite national recommendations for RSV vaccination in Ireland, they have not been implemented due to cost concerns and evidence gaps. We assessed RSV-SARI tertiary healthcare engagement to determine healthcare utilisation costs and potential savings in patients following RSV vaccination. Methods: RSV SARI admissions over two winter seasons (2024/25 and 2025/26) at a tertiary centre in Ireland were assessed. Sociodemographic and disease-specific variables were recorded, and their relationship with outcomes investigated. Potential cost offsets which may present following a successful RSV vaccination campaign were calculated. Results: There were 168 RSV admissions during the study (54% aged ≥75). Median length of stay was 6 days and was significantly longer in patients aged ≥75. Having a chronic neurological disease was associated with increased length of stay. The 90-day readmission rate was 24%. Vaccinating ≥75-year-olds in the hospital catchment area would cost €3,712,500, while predicted admission avoidance post-vaccination would save €1,197,692, or €111.77 per vaccine administered. Vaccine costs of €49 would be cost-neutral at the hospital level. Conclusions: RSV disproportionately affects patients ≥75 years of age. Projected vaccine cost offsets in this population are substantially different from those previously used to inform national policy.

MeSH

Respiratory Syncytial Viruses, Vaccines, Respiratory Tract Infections, Vaccination, Aged, Viruses, Length Of Stay, Infections